TAK-243

N/A

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameTAK-243
Drug Alias NameTAK-243MLN-7243
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 1 inhibitors
TargetsUbiquitin-like modifier-activating enzyme 1
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsSolid tumoursLymphoma, Non-HodgkinLymphoma
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A